Photo by cdc from unsplash
Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD) [1, 2]. In the case of surgery failure, additional treatment options are required [3–6]. Pasireotide has shown… Click to show full abstract
Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD) [1, 2]. In the case of surgery failure, additional treatment options are required [3–6]. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed [7–9]. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications.
Journal Title: Endocrine
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!